甲状腺癌治疗中耐药机制的挑战与应对策略
BRAFV600E、RAS突变及NTRK、RET、ALK、ROS1等激酶融合是甲状腺癌的可靶向驱动事件,酪氨酸激酶抑制剂初始有效后可能出现获得性耐药。获得性耐药机制包括靶点基因突变阻碍药物活性及旁路激酶信号通路上调,对耐药病灶(液体或组织)活检及分子分析有助于制定新治疗策略。无进展生存期因获得性耐药而缩短,临床医生需前瞻性识别驱动因素并表征靶点耐药机制。
要点
- BRAFV600E、N/H/K RAS突变及NTRK、RET、ALK、ROS1融合是甲状腺癌可靶向驱动事件。
- 获得性耐药机制包括靶点基因突变和旁路激酶信号通路上调。
- 对耐药病灶行液体或组织活检及分子分析可协助制定新治疗策略。
核心结论
- 无进展生存期因获得性耐药而缩短。
- 为减轻这一治疗局限,临床医生必须前瞻性识别驱动因素并表征靶点耐药机制。
主要发现
- BRAFV600E和N/H/K RAS突变以及涉及神经营养酪氨酸受体激酶(NTRK)、RET、间变性淋巴瘤激酶(ALK)和ROS1的致癌激酶融合已被确定为甲状腺癌的可靶向事件。
- 这些驱动改变导致癌基因成瘾,已通过酪氨酸激酶抑制剂成功利用。
- 初始应答后可能发生获得性耐药,需要治疗转向新疗法。
- 已发现若干获得性耐药发展途径,包括阻碍药物活性的靶点基因突变和导致肿瘤进展的旁路激酶信号通路上调。
- 对耐药病灶(液体或组织)活检及后续分子分析可协助制定新治疗策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: BRAFV600E and N/H/K RAS mutations and oncogenic kinase fusions involving neurotrophin tyrosine receptor kinase (NTRK), RET, anaplastic lymphoma kinase (ALK), and ROS1 have been identified as actionable targets in thyroid cancer. These driver alterations lead to oncogene addiction, which has been successfully exploited through tyrosine kinase inhibitors. Acquired resistance may develop following an initial response requiring a therapeutic pivot to new therapies. Summary: Several pathways for development of acquired resistance have been identified. These encompass acquired on-target gene mutation impeding drug activity and upregulation of bypass kinase signaling pathways leading to tumor progression. Biopsy of resistant lesions (liquid or tissue) and subsequent molecular analysis can assist with new therapeutic strategies. Conclusions: Progression-free survival is curtailed by developing acquired resistance. To minimize this therapeutic liability, clinicians must be anticipatory in identifying the drivers and characterizing mechanisms of on-target resistance.
引用
- Gild ML, Bullock M, Tsang V, et al. Challenges and Strategies to Combat Resistance Mechanisms in Thyroid Cancer Therapeutics. Thyroid. 2023. PMID: 36924302. doi:10.1089/thy.2022.0704
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。